Medtronic is working hard to make the MiniMed™ 670G system commercially available in autumn 2018 in UK and Ireland.

Although the MiniMed™ 670G system received CE Mark approval, the timing of availability in each country is pending local regulatory approvals. Furthermore, Medtronic is working hard to make the MiniMed™ 670G system available across the Europe, Middle East and Africa (EMEA) region. We will provide additional information once we are able to share more.

We are working closely with Healthcare Professionals to find the most appropriate time for them to receive training.

The MiniMed™ 670G insulin pump has been added to the CE certificate that contains all of Medtronic’s external pump certifications (QS EC certificate #8857). This certificate expires in July 2019 and will be renewed nearer the time as per usual protocol.

Medtronic is actively engaging with the reimbursement bodies and healthcare professionals as part of the commercialisation process and price details will be communicated as soon as the MiniMedTM 670G system is commercially released in the UK and Ireland

Although pre-ordering is not currently available for the MiniMed™ 670G system in UK and Ireland, you may want to start discussing your suitability to the MiniMed™ 670G system with your healthcare professional  as soon as it is commercially released in UK and Ireland.

The MiniMed™ 670G system automatically adjusts basal insulin delivery every five minutes, based on continuous glucose monitoring (CGM) readings, to offer protection against both highs and lows^2,3. It is the first and only system to automate and personalise the delivery of basal insulin 24 hours a day in people with type 1 diabetes.

If you are a healthcare professional we encourage you to visit our HCP Portal hcp.medtronic-diabetes.co.uk.

MiniMed™ 670G system is indicated for people with type 1 diabetes who are 7 years and above and are using a Total Daily Dose (TDD) of > 8 units per day. The MiniMed™ 670G system is not indicated during Pregnancy.

The MiniMed™ 670G system is not yet compatible for use with a mobile phone. Medtronic is currently developing a portfolio of Bluetooth insulin pumps that will be able to connect to mobile devices such as a mobile phone. We will announce further information as soon as further updates are available.

If you are a healthcare professional we encourage you to visit our HCP Portal hcp.medtronic-diabetes.co.uk

The MiniMed™ 670G system builds on Medtronic’s industry leading algorithms to offer therapy customization, so patients and healthcare professionals can choose from increasing levels of automation that best fit their diabetes management needs.

The MiniMed™ 670G system requires minimal input. Patients only need to enter mealtime carbohydrates, accept bolus correction recommendations, and periodically calibrate the sensor.

The MiniMed™ 670G system features SmartGuard™ Auto Mode, Medtronic’s most advanced SmartGuard™ algorithm to date, which enables the delivery of a variable rate of insulin 24 hours a day based on the personalized needs of each patient. This helps maximise the time glucose levels are within the target range², so that patients and their families can think less about managing their diabetes and spend more time on whatever day brings³.

Time in Range is the percentage of time that people with type 1 diabetes spend in the optimal glycemic range of 70-180 mg/dL (3.9-10 mmol/L). Increasing the Time in Range over the long-term can best be accomplished by using advances in diabetes therapies, like the MiniMed™ 670G system with SmartGuard™ technology, that automates basal insulin delivery^2,3.

The goal with diabetes management is to increase time spent in this healthy range and to minimize high and low sugar levels, which can lead to both immediate and long-term complications such as damage to blood vessels – increasing the risk of coronary artery disease, heart attack, and stroke^8,9. Damage to blood vessels can also lead to loss of vision, kidney disease, and nerve problems.

When your glucose level starts dropping to a pre-set low limit, the SmartGuard™ Suspend before Low feature will temporarily stop delivering insulin. It will also start delivering insulin again once your glucose stabilizes.

You should discuss any potential for transition and suitability to the new MiniMed™ 670G system with your healthcare professional.

You should discuss any potential for transition and suitability to the new MiniMed™ 670G system with your healthcare professional.

The MiniMed™ 670G system includes the new Guardian™ Sensor 3, the first and only sensor receiving FDA and CE Mark approval to control a hybrid closed loop system. The Guardian™ Sensor 3 is Medtronic’s most accurate⁵ sensor that drives our exclusive SmartGuard™ technology with a smart and reliable design⁵ and increased comfort.

The Guardian™ Sensor 3 is not part of the Enlite™ family of sensors. It is the first and only sensor with FDA and CE Mark approval to control a hybrid closed loop system. The Guardian™ Sensor 3 is Medtronic’s most accurate⁵ sensor and drives our exclusive SmartGuard™ technology. It has a smart and reliable design⁶ with increased comfort.

The Guardian™ Sensor 3 is only compatible with the MiniMed™ 640G insulin pump when used in conjunction with the new Guardian™ Link 3 transmitter. If you have an existing Guardian™ 2 Link then the Guardian™ Sensor 3 will not work with your MiniMed™ 640G insulin pump.

The Guardian™ Sensor 3 is only compatible with the MiniMed™ 640G insulin pump when used in conjunction with the new Guardian™ Link 3 transmitter. If you have an existing Guardian 2 Link then the Guardian™ Sensor 3 will not work with your MiniMed™ 640G insulin pump.

The new Guardian™ Sensor 3 will become available in some countries over the coming months earlier than the MiniMed™ 670G System so that MiniMed™ 640G system users can start to use the Guardian™ Sensor 3. More information will be shared at a later date.